UroGen Pharma Ltd. (URGN) 10-Year Financial Performance & Capital Metrics

URGN • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsSolid Tumor Oncology

AboutUroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102, which is in Phase III clinical trials for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. It is also developing UGN-301 for the treatment of high-grade non-muscle invasive bladder cancer. The company has a license agreement with Allergan Pharmaceuticals International Limited for developing and commercializing pharmaceutical products that contain RTGel and clostridial toxins; Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and strategic research collaboration with MD Anderson to advance investigational treatment for high-grade bladder cancer. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.Show more

Revenue $90M +9.3%
EBITDA -$96M -51.1%
Net Income -$127M -24.1%
EPS (Diluted) -2.96 +16.6%
Gross Margin 90.18% +1.7%
EBITDA Margin -106.7% -38.3%
Operating Margin -107.06% -35.1%
Net Margin -140.35% -13.5%
ROE -
ROIC -
Debt/Equity -
Interest Coverage -7.73 -73.6%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Momentum leader: RS Rating 82 (top 18%)
✓Strong 5Y sales CAGR of 449.8%

✗Weaknesses

✗Negative free cash flow
✗Shares diluted 48.7% in last year
✗Trading more than 30% below 52-week high

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y449.77%

3Y23.46%

TTM-19.09%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM0.59%

EPS CAGR

10Y-

5Y-

3Y-

TTM-9.84%

ROCE

10Y Avg-69.77%

5Y Avg-71.79%

3Y Avg-58.76%

Latest-50.03%

Peer Comparison

Solid Tumor Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
TLXTelix Pharmaceuticals Limited	2.49B	7.43	53.07	55.85%	3.98%	15.63%	0.36%	1.02
EXELExelixis, Inc.	12.18B	45.44	25.82	18.49%	29.63%	31.37%	5.2%	0.09
BBOTBridgeBio Oncology Therapeutics Inc.	919.87M	11.50	25			-25.73%
INBXInhibrx Biosciences, Inc.	1.04B	71.80	0.62	-88.89%	-110.78%	-421.09%		0.06
NUVBNuvation Bio Inc.	2.1B	6.14	-2.91		-8.13%	-66.74%		0.02
RLAYRelay Therapeutics, Inc.	1.32B	7.63	-3.23	-60.83%	-26.71%	-48.97%		0.06
ORICORIC Pharmaceuticals, Inc.	1.12B	11.52	-6.30			-33.24%		0.01
ZLABZai Lab Limited	2.09B	18.82	-7.24	49.59%	-46.83%	-27.21%		0.18

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	17.53M	8.16M	1.13M	18K	11.8M	48.04M	64.36M	82.71M	90.4M
Revenue Growth %	-	-	-0.53%	-0.86%	-0.98%	654.5%	3.07%	0.34%	0.29%	0.09%
Cost of Goods Sold+	113K	28K	600K	1.8M	0	1.01M	5.16M	7.65M	9.36M	8.88M
COGS % of Revenue	-	0%	0.07%	1.6%	-	0.09%	0.11%	0.12%	0.11%	0.1%
Gross Profit+	-113K	17.5M	7.56M	-675K	18K	10.79M	42.88M	56.7M	73.35M	81.52M
Gross Margin %	-	1%	0.93%	-0.6%	1%	0.91%	0.89%	0.88%	0.89%	0.9%
Gross Profit Growth %	-	155.88%	-0.57%	-1.09%	1.03%	598.44%	2.97%	0.32%	0.29%	0.11%
Operating Expenses+	12.41M	16.7M	27.51M	76.5M	109.5M	137.53M	135.18M	135.74M	138.89M	178.3M
OpEx % of Revenue	-	0.95%	3.37%	67.82%	6083.11%	11.66%	2.81%	2.11%	1.68%	1.97%
Selling, General & Admin	1.9M	6.42M	8.81M	39.57M	60.2M	90.22M	0	82.84M	93.27M	0
SG&A % of Revenue	-	0.37%	1.08%	35.08%	3344.39%	7.65%	-	1.29%	1.13%	-
Research & Development	10.52M	10.29M	18.7M	36.93M	49.3M	47.31M	47.64M	52.91M	45.61M	57.15M
R&D % of Revenue	-	0.59%	2.29%	32.74%	2738.72%	4.01%	0.99%	0.82%	0.55%	0.63%
Other Operating Expenses	0	0	0	0	0	0	87.53M	0	0	121.15M
Operating Income+	-12.41M	798K	-19.95M	-77.18M	-109.48M	-126.74M	-92.29M	-79.04M	-65.54M	-96.78M
Operating Margin %	-	0.05%	-2.45%	-68.42%	-6082.11%	-10.74%	-1.92%	-1.23%	-0.79%	-1.07%
Operating Income Growth %	-1.84%	1.06%	-26%	-2.87%	-0.42%	-0.16%	0.27%	0.14%	0.17%	-0.48%
EBITDA+	-12.3M	1.01M	-19.74M	-76.76M	-108.15M	-124.69M	-91.46M	-77.22M	-63.83M	-96.45M
EBITDA Margin %	-	0.06%	-2.42%	-68.05%	-6008.56%	-10.57%	-1.9%	-1.2%	-0.77%	-1.07%
EBITDA Growth %	-1.83%	1.08%	-20.53%	-2.89%	-0.41%	-0.15%	0.27%	0.16%	0.17%	-0.51%
D&A (Non-Cash Add-back)	113K	213K	207K	417K	1.32M	2.04M	831K	1.82M	1.71M	329K
EBIT	-12.41M	798K	-19.95M	-77.18M	-109.48M	-124.75M	-92.29M	-78.03M	-62.06M	-95.68M
Net Interest Income+	0	1K	125K	1.87M	4.33M	1.63M	365K	-7.5M	-12.07M	-3.62M
Interest Income	0	1K	125K	1.87M	4.62M	1.99M	365K	938K	2.64M	8.9M
Interest Expense	0	0	0	0	284K	357K	0	8.44M	14.71M	12.52M
Other Income/Expense	-279K	-2.74M	-31K	1.65M	4.33M	1.63M	-17.08M	-28.99M	-32.79M	-27.26M
Pretax Income+	-12.69M	-1.94M	-19.98M	-75.53M	-105.15M	-125.11M	-109.37M	-108.03M	-98.32M	-124.04M
Pretax Margin %	-	-0.11%	-2.45%	-66.96%	-5841.44%	-10.6%	-2.28%	-1.68%	-1.19%	-1.37%
Income Tax+	0	0	19K	125K	0	3.37M	1.45M	1.75M	3.92M	2.83M
Effective Tax Rate %	1%	1%	1%	1%	1%	1.03%	1.01%	1.02%	1.04%	1.02%
Net Income+	-12.69M	-1.94M	-20M	-75.66M	-105.15M	-128.48M	-110.82M	-109.78M	-102.24M	-126.87M
Net Margin %	-	-0.11%	-2.45%	-67.07%	-5841.44%	-10.89%	-2.31%	-1.71%	-1.24%	-1.4%
Net Income Growth %	-1.78%	0.85%	-9.3%	-2.78%	-0.39%	-0.22%	0.14%	0.01%	0.07%	-0.24%
Net Income (Continuing)	-12.69M	-1.94M	-20M	-75.66M	-105.15M	-128.48M	-110.82M	-109.78M	-102.24M	-126.87M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-5.51	-0.16	-2.06	-4.80	-4.90	-5.90	-4.96	-4.79	-3.55	-2.96
EPS Growth %	-1.78%	0.97%	-11.88%	-1.33%	-0.02%	-0.2%	0.16%	0.03%	0.26%	0.17%
EPS (Basic)	-5.51	-0.16	-2.06	-4.80	-4.90	-5.90	-4.96	-4.79	-3.55	-2.96
Diluted Shares Outstanding	2.3M	11.97M	9.72M	15.75M	20.53M	21.78M	22.35M	22.81M	28.83M	42.88M
Basic Shares Outstanding	2.3M	11.97M	9.72M	15.75M	20.53M	21.78M	22.35M	22.81M	28.83M	42.88M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	19.13M	22.04M	74.47M	102.24M	148.63M	115.62M	114.39M	128.91M	169.19M	276.13M
Cash & Short-Term Investments	17.98M	21.36M	73M	101.32M	147.08M	102.02M	89.14M	99.96M	136.97M	236.69M
Cash Only	17.98M	21.36M	37M	101.32M	49.69M	52.86M	44.36M	55.41M	95M	171.99M
Short-Term Investments	0	0	36M	0	97.39M	49.15M	44.78M	44.56M	41.97M	64.7M
Accounts Receivable	0	83K	0	0	0	7.05M	11.72M	12.7M	15.44M	20.3M
Days Sales Outstanding	-	1.73	-	-	-	218	89.02	72.05	68.15	81.97
Inventory	0	105K	316K	0	0	1.96M	4.83M	4.33M	5.67M	9.23M
Days Inventory Outstanding	-	1.37K	192.23	-	-	710.47	342	206.25	221.2	379.22
Other Current Assets	21K	95K	198K	253K	523K	1.23M	1.23M	11.91M	11.1M	9.92M
Total Non-Current Assets+	259K	1.01M	1.08M	1.32M	53.75M	6.39M	5.36M	6.71M	9.13M	9.58M
Property, Plant & Equipment	259K	741K	805K	948K	4.71M	4.2M	3.15M	3.75M	2.36M	3.79M
Fixed Asset Turnover	-	23.66x	10.13x	1.19x	0.00x	2.81x	15.27x	17.17x	35.05x	23.86x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	0	24K	29K	51K	48.55M	1.89M	675K	0	4.5M	5.02M
Other Non-Current Assets	0	250K	244K	317K	487K	289K	1.53M	2.96M	2.26M	765K
Total Assets+	19.39M	23.06M	75.55M	103.56M	202.39M	122M	119.75M	135.62M	178.31M	285.71M
Asset Turnover	-	0.76x	0.11x	0.01x	0.00x	0.10x	0.40x	0.47x	0.46x	0.32x
Asset Growth %	3.45%	0.19%	2.28%	0.37%	0.95%	-0.4%	-0.02%	0.13%	0.31%	0.6%
Total Current Liabilities+	2.24M	3.14M	7.04M	13.46M	19.48M	21.44M	22.38M	23.92M	31.21M	45.95M
Accounts Payable	1.72M	1.88M	2.84M	4.27M	4.69M	3.27M	5.79M	5.53M	6.51M	10.93M
Days Payables Outstanding	5.54K	24.51K	1.73K	864.83	-	1.18K	409.52	263.57	253.99	449.25
Short-Term Debt	0	0	0	0	0	0	0	0	0	0
Deferred Revenue (Current)	0	0	650K	0	0	0	0	0	0	0
Other Current Liabilities	0	570K	-1.6M	0	1.58M	11.41M	10.28M	11.53M	14.67M	18.52M
Current Ratio	8.55x	7.03x	10.59x	7.59x	7.63x	5.39x	5.11x	5.39x	5.42x	6.01x
Quick Ratio	8.55x	6.99x	10.54x	7.59x	7.63x	5.30x	4.90x	5.21x	5.24x	5.81x
Cash Conversion Cycle	-	-23.14K	-	-	-	-254.8	21.5	14.73	35.36	11.94
Total Non-Current Liabilities+	0	3.61M	0	0	2.6M	4.21M	88.95M	201.06M	212.31M	248.56M
Long-Term Debt	0	0	0	0	0	0	0	97.54M	98.55M	121.73M
Capital Lease Obligations	0	0	0	0	2.6M	1.5M	398K	1.59M	844K	1.65M
Deferred Tax Liabilities	0	0	0	0	0	2.72M	2.84M	3.02M	0	0
Other Non-Current Liabilities	0	3.61M	0	0	0	0	85.71M	98.92M	112.92M	125.18M
Total Liabilities	2.24M	6.75M	7.04M	13.46M	22.09M	25.65M	111.33M	224.98M	243.52M	294.51M
Total Debt+	0	0	0	0	2.6M	1.5M	398K	99.12M	99.39M	123.39M
Net Debt	-17.98M	-21.36M	-37M	-101.32M	-47.08M	-51.37M	-43.96M	43.72M	4.39M	-48.6M
Debt / Equity	-	-	-	-	0.01x	0.02x	0.05x	-	-	-
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-21.13x	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-	-	-385.49x	-355.01x	-	-9.37x	-4.45x	-7.73x
Total Equity+	17.15M	16.31M	68.52M	90.09M	180.3M	96.36M	8.41M	-89.36M	-65.21M	-8.8M
Equity Growth %	3.95%	-0.05%	3.2%	0.31%	1%	-0.47%	-0.91%	-11.62%	0.27%	0.87%
Book Value per Share	7.45	1.36	7.05	5.72	8.78	4.42	0.38	-3.92	-2.26	-0.21
Total Shareholders' Equity	17.15M	16.31M	68.52M	90.09M	180.3M	96.36M	8.41M	-89.36M	-65.21M	-8.8M
Common Stock	2K	6K	37K	44K	57K	60K	61K	63K	89K	115K
Retained Earnings	-25.27M	-27.21M	-47.21M	-122.87M	-228.02M	-356.5M	-467.32M	-577.1M	-679.35M	-806.22M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	0	-370K	-577K	-747K	276K	271K	-25K	-107K	12K	56K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-7.17M	4.19M	-9.57M	-37.33M	-71.02M	-105.89M	-84.89M	-87.56M	-76.38M	-96.77M
Operating CF Margin %	-	0.24%	-1.17%	-33.1%	-3945.39%	-8.97%	-1.77%	-1.36%	-0.92%	-1.07%
Operating CF Growth %	-0.74%	1.58%	-3.28%	-2.9%	-0.9%	-0.49%	0.2%	-0.03%	0.13%	-0.27%
Net Income	-12.69M	-1.94M	-20M	-75.66M	-105.15M	-128.48M	-110.82M	-109.78M	-102.24M	-126.87M
Depreciation & Amortization	113K	213K	207K	417K	1.32M	2.04M	1.77M	1.82M	1.71M	1.19M
Stock-Based Compensation	449K	1.97M	6.3M	30.64M	29.97M	28.02M	23.11M	10.58M	9.34M	13.11M
Deferred Taxes	240K	0	0	0	-572K	439K	15.32M	0	0	0
Other Non-Cash Items	4.1M	2.74M	165K	100K	-910K	-1.54M	-1.18M	16.13M	11.48M	10.88M
Working Capital Changes	609K	1.21M	3.76M	7.16M	4.32M	-6.37M	-13.11M	-6.31M	3.34M	4.93M
Change in Receivables	0	-83K	83K	3.29M	0	-7.05M	-4.67M	-987K	-2.74M	-4.86M
Change in Inventory	0	-105K	-211K	316K	0	-1.96M	-2.87M	-362K	-1.35M	-3.55M
Change in Payables	1.16M	481K	2.53M	4.21M	2.93M	-1.25M	2M	281K	4.16M	10.89M
Cash from Investing+	-301K	-793K	-36.38M	35.29M	-145.59M	93.24M	4.07M	1.06M	-953K	-20.61M
Capital Expenditures	-301K	-695K	-271K	-560K	-325K	-1.22M	-752K	-254K	-194K	-295K
CapEx % of Revenue	-	0.04%	0.03%	0.5%	18.06%	0.1%	0.02%	0%	0%	0%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	-98K	-105K	-54K	-172K	94.45M	4.82M	1.31M	0	0
Cash from Financing+	21.58M	-9K	61.59M	66.42M	165.25M	16.53M	72.32M	97.13M	116.93M	194.62M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	0	-9K	744K	2.19M	3.59M	674K	72.4M	0	49.57M	18.96M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-7.48M	3.49M	-9.84M	-37.89M	-71.34M	-107.1M	-85.64M	-87.81M	-76.57M	-97.06M
FCF Margin %	-	0.2%	-1.21%	-33.59%	-3963.44%	-9.08%	-1.78%	-1.36%	-0.93%	-1.07%
FCF Growth %	-0.81%	1.47%	-3.82%	-2.85%	-0.88%	-0.5%	0.2%	-0.03%	0.13%	-0.27%
FCF per Share	-3.25	0.29	-1.01	-2.41	-3.48	-4.92	-3.83	-3.85	-2.66	-2.26
FCF Conversion (FCF/Net Income)	0.57x	-2.16x	0.48x	0.49x	0.68x	0.82x	0.77x	0.80x	0.75x	0.76x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-123.07%	-11.6%	-47.16%	-95.4%	-77.77%	-92.88%	-211.55%	-	-	-
Return on Invested Capital (ROIC)	-	-	-113.09%	-570.52%	-134.61%	-106.68%	-1466.66%	-	-	-
Gross Margin	-	99.84%	92.65%	-59.84%	100%	91.45%	89.27%	88.11%	88.68%	90.18%
Net Margin	-	-11.07%	-245.16%	-6707.18%	-584144.44%	-1088.94%	-230.67%	-170.58%	-123.61%	-140.35%
Debt / Equity	-	-	-	-	0.01x	0.02x	0.05x	-	-	-
Interest Coverage	-	-	-	-	-385.49x	-355.01x	-	-9.37x	-4.45x	-7.73x
FCF Conversion	0.57x	-2.16x	0.48x	0.49x	0.68x	0.82x	0.77x	0.80x	0.75x	0.76x
Revenue Growth	-	-	-53.46%	-86.17%	-98.4%	65450%	307.17%	33.96%	28.52%	9.29%

Revenue by Segment

	2018	2021	2022	2023	2024
Jelmyto	-	48.04M	64.36M	82.71M	90.4M
Jelmyto Growth	-	-	33.96%	28.52%	9.29%
R T Gel	1.1M	-	-	-	-
R T Gel Growth	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

UroGen Pharma Ltd. (URGN) reported $72.3M in revenue for fiscal year 2024.

UroGen Pharma Ltd. (URGN) grew revenue by 9.3% over the past year. This is steady growth.

UroGen Pharma Ltd. (URGN) reported a net loss of $114.7M for fiscal year 2024.

Dividend & Returns

UroGen Pharma Ltd. (URGN) had negative free cash flow of $138.1M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

UroGen Pharma Ltd. (URGN) 10-Year Financial Performance & Capital Metrics

URGN • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsSolid Tumor Oncology

Revenue $90M +9.3%
EBITDA -$96M -51.1%
Net Income -$127M -24.1%
EPS (Diluted) -2.96 +16.6%
Gross Margin 90.18% +1.7%
EBITDA Margin -106.7% -38.3%
Operating Margin -107.06% -35.1%
Net Margin -140.35% -13.5%
ROE -
ROIC -
Debt/Equity -
Interest Coverage -7.73 -73.6%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Momentum leader: RS Rating 82 (top 18%)
✓Strong 5Y sales CAGR of 449.8%

✗Weaknesses

✗Negative free cash flow
✗Shares diluted 48.7% in last year
✗Trading more than 30% below 52-week high

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y449.77%

3Y23.46%

TTM-19.09%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM0.59%

EPS CAGR

10Y-

5Y-

3Y-

TTM-9.84%

ROCE

10Y Avg-69.77%

5Y Avg-71.79%

3Y Avg-58.76%

Latest-50.03%

Peer Comparison

Solid Tumor Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
TLXTelix Pharmaceuticals Limited	2.49B	7.43	53.07	55.85%	3.98%	15.63%	0.36%	1.02
EXELExelixis, Inc.	12.18B	45.44	25.82	18.49%	29.63%	31.37%	5.2%	0.09
BBOTBridgeBio Oncology Therapeutics Inc.	919.87M	11.50	25			-25.73%
INBXInhibrx Biosciences, Inc.	1.04B	71.80	0.62	-88.89%	-110.78%	-421.09%		0.06
NUVBNuvation Bio Inc.	2.1B	6.14	-2.91		-8.13%	-66.74%		0.02
RLAYRelay Therapeutics, Inc.	1.32B	7.63	-3.23	-60.83%	-26.71%	-48.97%		0.06
ORICORIC Pharmaceuticals, Inc.	1.12B	11.52	-6.30			-33.24%		0.01
ZLABZai Lab Limited	2.09B	18.82	-7.24	49.59%	-46.83%	-27.21%		0.18

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	17.53M	8.16M	1.13M	18K	11.8M	48.04M	64.36M	82.71M	90.4M
Revenue Growth %	-	-	-0.53%	-0.86%	-0.98%	654.5%	3.07%	0.34%	0.29%	0.09%
Cost of Goods Sold+	113K	28K	600K	1.8M	0	1.01M	5.16M	7.65M	9.36M	8.88M
COGS % of Revenue	-	0%	0.07%	1.6%	-	0.09%	0.11%	0.12%	0.11%	0.1%
Gross Profit+	-113K	17.5M	7.56M	-675K	18K	10.79M	42.88M	56.7M	73.35M	81.52M
Gross Margin %	-	1%	0.93%	-0.6%	1%	0.91%	0.89%	0.88%	0.89%	0.9%
Gross Profit Growth %	-	155.88%	-0.57%	-1.09%	1.03%	598.44%	2.97%	0.32%	0.29%	0.11%
Operating Expenses+	12.41M	16.7M	27.51M	76.5M	109.5M	137.53M	135.18M	135.74M	138.89M	178.3M
OpEx % of Revenue	-	0.95%	3.37%	67.82%	6083.11%	11.66%	2.81%	2.11%	1.68%	1.97%
Selling, General & Admin	1.9M	6.42M	8.81M	39.57M	60.2M	90.22M	0	82.84M	93.27M	0
SG&A % of Revenue	-	0.37%	1.08%	35.08%	3344.39%	7.65%	-	1.29%	1.13%	-
Research & Development	10.52M	10.29M	18.7M	36.93M	49.3M	47.31M	47.64M	52.91M	45.61M	57.15M
R&D % of Revenue	-	0.59%	2.29%	32.74%	2738.72%	4.01%	0.99%	0.82%	0.55%	0.63%
Other Operating Expenses	0	0	0	0	0	0	87.53M	0	0	121.15M
Operating Income+	-12.41M	798K	-19.95M	-77.18M	-109.48M	-126.74M	-92.29M	-79.04M	-65.54M	-96.78M
Operating Margin %	-	0.05%	-2.45%	-68.42%	-6082.11%	-10.74%	-1.92%	-1.23%	-0.79%	-1.07%
Operating Income Growth %	-1.84%	1.06%	-26%	-2.87%	-0.42%	-0.16%	0.27%	0.14%	0.17%	-0.48%
EBITDA+	-12.3M	1.01M	-19.74M	-76.76M	-108.15M	-124.69M	-91.46M	-77.22M	-63.83M	-96.45M
EBITDA Margin %	-	0.06%	-2.42%	-68.05%	-6008.56%	-10.57%	-1.9%	-1.2%	-0.77%	-1.07%
EBITDA Growth %	-1.83%	1.08%	-20.53%	-2.89%	-0.41%	-0.15%	0.27%	0.16%	0.17%	-0.51%
D&A (Non-Cash Add-back)	113K	213K	207K	417K	1.32M	2.04M	831K	1.82M	1.71M	329K
EBIT	-12.41M	798K	-19.95M	-77.18M	-109.48M	-124.75M	-92.29M	-78.03M	-62.06M	-95.68M
Net Interest Income+	0	1K	125K	1.87M	4.33M	1.63M	365K	-7.5M	-12.07M	-3.62M
Interest Income	0	1K	125K	1.87M	4.62M	1.99M	365K	938K	2.64M	8.9M
Interest Expense	0	0	0	0	284K	357K	0	8.44M	14.71M	12.52M
Other Income/Expense	-279K	-2.74M	-31K	1.65M	4.33M	1.63M	-17.08M	-28.99M	-32.79M	-27.26M
Pretax Income+	-12.69M	-1.94M	-19.98M	-75.53M	-105.15M	-125.11M	-109.37M	-108.03M	-98.32M	-124.04M
Pretax Margin %	-	-0.11%	-2.45%	-66.96%	-5841.44%	-10.6%	-2.28%	-1.68%	-1.19%	-1.37%
Income Tax+	0	0	19K	125K	0	3.37M	1.45M	1.75M	3.92M	2.83M
Effective Tax Rate %	1%	1%	1%	1%	1%	1.03%	1.01%	1.02%	1.04%	1.02%
Net Income+	-12.69M	-1.94M	-20M	-75.66M	-105.15M	-128.48M	-110.82M	-109.78M	-102.24M	-126.87M
Net Margin %	-	-0.11%	-2.45%	-67.07%	-5841.44%	-10.89%	-2.31%	-1.71%	-1.24%	-1.4%
Net Income Growth %	-1.78%	0.85%	-9.3%	-2.78%	-0.39%	-0.22%	0.14%	0.01%	0.07%	-0.24%
Net Income (Continuing)	-12.69M	-1.94M	-20M	-75.66M	-105.15M	-128.48M	-110.82M	-109.78M	-102.24M	-126.87M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-5.51	-0.16	-2.06	-4.80	-4.90	-5.90	-4.96	-4.79	-3.55	-2.96
EPS Growth %	-1.78%	0.97%	-11.88%	-1.33%	-0.02%	-0.2%	0.16%	0.03%	0.26%	0.17%
EPS (Basic)	-5.51	-0.16	-2.06	-4.80	-4.90	-5.90	-4.96	-4.79	-3.55	-2.96
Diluted Shares Outstanding	2.3M	11.97M	9.72M	15.75M	20.53M	21.78M	22.35M	22.81M	28.83M	42.88M
Basic Shares Outstanding	2.3M	11.97M	9.72M	15.75M	20.53M	21.78M	22.35M	22.81M	28.83M	42.88M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	19.13M	22.04M	74.47M	102.24M	148.63M	115.62M	114.39M	128.91M	169.19M	276.13M
Cash & Short-Term Investments	17.98M	21.36M	73M	101.32M	147.08M	102.02M	89.14M	99.96M	136.97M	236.69M
Cash Only	17.98M	21.36M	37M	101.32M	49.69M	52.86M	44.36M	55.41M	95M	171.99M
Short-Term Investments	0	0	36M	0	97.39M	49.15M	44.78M	44.56M	41.97M	64.7M
Accounts Receivable	0	83K	0	0	0	7.05M	11.72M	12.7M	15.44M	20.3M
Days Sales Outstanding	-	1.73	-	-	-	218	89.02	72.05	68.15	81.97
Inventory	0	105K	316K	0	0	1.96M	4.83M	4.33M	5.67M	9.23M
Days Inventory Outstanding	-	1.37K	192.23	-	-	710.47	342	206.25	221.2	379.22
Other Current Assets	21K	95K	198K	253K	523K	1.23M	1.23M	11.91M	11.1M	9.92M
Total Non-Current Assets+	259K	1.01M	1.08M	1.32M	53.75M	6.39M	5.36M	6.71M	9.13M	9.58M
Property, Plant & Equipment	259K	741K	805K	948K	4.71M	4.2M	3.15M	3.75M	2.36M	3.79M
Fixed Asset Turnover	-	23.66x	10.13x	1.19x	0.00x	2.81x	15.27x	17.17x	35.05x	23.86x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	0	24K	29K	51K	48.55M	1.89M	675K	0	4.5M	5.02M
Other Non-Current Assets	0	250K	244K	317K	487K	289K	1.53M	2.96M	2.26M	765K
Total Assets+	19.39M	23.06M	75.55M	103.56M	202.39M	122M	119.75M	135.62M	178.31M	285.71M
Asset Turnover	-	0.76x	0.11x	0.01x	0.00x	0.10x	0.40x	0.47x	0.46x	0.32x
Asset Growth %	3.45%	0.19%	2.28%	0.37%	0.95%	-0.4%	-0.02%	0.13%	0.31%	0.6%
Total Current Liabilities+	2.24M	3.14M	7.04M	13.46M	19.48M	21.44M	22.38M	23.92M	31.21M	45.95M
Accounts Payable	1.72M	1.88M	2.84M	4.27M	4.69M	3.27M	5.79M	5.53M	6.51M	10.93M
Days Payables Outstanding	5.54K	24.51K	1.73K	864.83	-	1.18K	409.52	263.57	253.99	449.25
Short-Term Debt	0	0	0	0	0	0	0	0	0	0
Deferred Revenue (Current)	0	0	650K	0	0	0	0	0	0	0
Other Current Liabilities	0	570K	-1.6M	0	1.58M	11.41M	10.28M	11.53M	14.67M	18.52M
Current Ratio	8.55x	7.03x	10.59x	7.59x	7.63x	5.39x	5.11x	5.39x	5.42x	6.01x
Quick Ratio	8.55x	6.99x	10.54x	7.59x	7.63x	5.30x	4.90x	5.21x	5.24x	5.81x
Cash Conversion Cycle	-	-23.14K	-	-	-	-254.8	21.5	14.73	35.36	11.94
Total Non-Current Liabilities+	0	3.61M	0	0	2.6M	4.21M	88.95M	201.06M	212.31M	248.56M
Long-Term Debt	0	0	0	0	0	0	0	97.54M	98.55M	121.73M
Capital Lease Obligations	0	0	0	0	2.6M	1.5M	398K	1.59M	844K	1.65M
Deferred Tax Liabilities	0	0	0	0	0	2.72M	2.84M	3.02M	0	0
Other Non-Current Liabilities	0	3.61M	0	0	0	0	85.71M	98.92M	112.92M	125.18M
Total Liabilities	2.24M	6.75M	7.04M	13.46M	22.09M	25.65M	111.33M	224.98M	243.52M	294.51M
Total Debt+	0	0	0	0	2.6M	1.5M	398K	99.12M	99.39M	123.39M
Net Debt	-17.98M	-21.36M	-37M	-101.32M	-47.08M	-51.37M	-43.96M	43.72M	4.39M	-48.6M
Debt / Equity	-	-	-	-	0.01x	0.02x	0.05x	-	-	-
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-21.13x	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-	-	-385.49x	-355.01x	-	-9.37x	-4.45x	-7.73x
Total Equity+	17.15M	16.31M	68.52M	90.09M	180.3M	96.36M	8.41M	-89.36M	-65.21M	-8.8M
Equity Growth %	3.95%	-0.05%	3.2%	0.31%	1%	-0.47%	-0.91%	-11.62%	0.27%	0.87%
Book Value per Share	7.45	1.36	7.05	5.72	8.78	4.42	0.38	-3.92	-2.26	-0.21
Total Shareholders' Equity	17.15M	16.31M	68.52M	90.09M	180.3M	96.36M	8.41M	-89.36M	-65.21M	-8.8M
Common Stock	2K	6K	37K	44K	57K	60K	61K	63K	89K	115K
Retained Earnings	-25.27M	-27.21M	-47.21M	-122.87M	-228.02M	-356.5M	-467.32M	-577.1M	-679.35M	-806.22M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	0	-370K	-577K	-747K	276K	271K	-25K	-107K	12K	56K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-7.17M	4.19M	-9.57M	-37.33M	-71.02M	-105.89M	-84.89M	-87.56M	-76.38M	-96.77M
Operating CF Margin %	-	0.24%	-1.17%	-33.1%	-3945.39%	-8.97%	-1.77%	-1.36%	-0.92%	-1.07%
Operating CF Growth %	-0.74%	1.58%	-3.28%	-2.9%	-0.9%	-0.49%	0.2%	-0.03%	0.13%	-0.27%
Net Income	-12.69M	-1.94M	-20M	-75.66M	-105.15M	-128.48M	-110.82M	-109.78M	-102.24M	-126.87M
Depreciation & Amortization	113K	213K	207K	417K	1.32M	2.04M	1.77M	1.82M	1.71M	1.19M
Stock-Based Compensation	449K	1.97M	6.3M	30.64M	29.97M	28.02M	23.11M	10.58M	9.34M	13.11M
Deferred Taxes	240K	0	0	0	-572K	439K	15.32M	0	0	0
Other Non-Cash Items	4.1M	2.74M	165K	100K	-910K	-1.54M	-1.18M	16.13M	11.48M	10.88M
Working Capital Changes	609K	1.21M	3.76M	7.16M	4.32M	-6.37M	-13.11M	-6.31M	3.34M	4.93M
Change in Receivables	0	-83K	83K	3.29M	0	-7.05M	-4.67M	-987K	-2.74M	-4.86M
Change in Inventory	0	-105K	-211K	316K	0	-1.96M	-2.87M	-362K	-1.35M	-3.55M
Change in Payables	1.16M	481K	2.53M	4.21M	2.93M	-1.25M	2M	281K	4.16M	10.89M
Cash from Investing+	-301K	-793K	-36.38M	35.29M	-145.59M	93.24M	4.07M	1.06M	-953K	-20.61M
Capital Expenditures	-301K	-695K	-271K	-560K	-325K	-1.22M	-752K	-254K	-194K	-295K
CapEx % of Revenue	-	0.04%	0.03%	0.5%	18.06%	0.1%	0.02%	0%	0%	0%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	-98K	-105K	-54K	-172K	94.45M	4.82M	1.31M	0	0
Cash from Financing+	21.58M	-9K	61.59M	66.42M	165.25M	16.53M	72.32M	97.13M	116.93M	194.62M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	0	-9K	744K	2.19M	3.59M	674K	72.4M	0	49.57M	18.96M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-7.48M	3.49M	-9.84M	-37.89M	-71.34M	-107.1M	-85.64M	-87.81M	-76.57M	-97.06M
FCF Margin %	-	0.2%	-1.21%	-33.59%	-3963.44%	-9.08%	-1.78%	-1.36%	-0.93%	-1.07%
FCF Growth %	-0.81%	1.47%	-3.82%	-2.85%	-0.88%	-0.5%	0.2%	-0.03%	0.13%	-0.27%
FCF per Share	-3.25	0.29	-1.01	-2.41	-3.48	-4.92	-3.83	-3.85	-2.66	-2.26
FCF Conversion (FCF/Net Income)	0.57x	-2.16x	0.48x	0.49x	0.68x	0.82x	0.77x	0.80x	0.75x	0.76x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-123.07%	-11.6%	-47.16%	-95.4%	-77.77%	-92.88%	-211.55%	-	-	-
Return on Invested Capital (ROIC)	-	-	-113.09%	-570.52%	-134.61%	-106.68%	-1466.66%	-	-	-
Gross Margin	-	99.84%	92.65%	-59.84%	100%	91.45%	89.27%	88.11%	88.68%	90.18%
Net Margin	-	-11.07%	-245.16%	-6707.18%	-584144.44%	-1088.94%	-230.67%	-170.58%	-123.61%	-140.35%
Debt / Equity	-	-	-	-	0.01x	0.02x	0.05x	-	-	-
Interest Coverage	-	-	-	-	-385.49x	-355.01x	-	-9.37x	-4.45x	-7.73x
FCF Conversion	0.57x	-2.16x	0.48x	0.49x	0.68x	0.82x	0.77x	0.80x	0.75x	0.76x
Revenue Growth	-	-	-53.46%	-86.17%	-98.4%	65450%	307.17%	33.96%	28.52%	9.29%

Revenue by Segment

	2018	2021	2022	2023	2024
Jelmyto	-	48.04M	64.36M	82.71M	90.4M
Jelmyto Growth	-	-	33.96%	28.52%	9.29%
R T Gel	1.1M	-	-	-	-
R T Gel Growth	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

UroGen Pharma Ltd. (URGN) reported $72.3M in revenue for fiscal year 2024.

UroGen Pharma Ltd. (URGN) grew revenue by 9.3% over the past year. This is steady growth.

UroGen Pharma Ltd. (URGN) reported a net loss of $114.7M for fiscal year 2024.

Dividend & Returns

UroGen Pharma Ltd. (URGN) had negative free cash flow of $138.1M in fiscal year 2024, likely due to heavy capital investments.